A Wegovy denial feels final, but it usually is not. Most denials fall into a handful of categories, and several of them are workable if you know what the plan actually objected to. The trick is to stop guessing and start with the denial letter itself.
Why Wegovy gets denied
The most common reason has nothing to do with you and everything to do with a label. Wegovy and Ozempic are the same molecule, semaglutide, but Wegovy is approved for weight management and Ozempic for type 2 diabetes. Plans treat those two indications very differently. On the ACA Marketplace, an analysis found that about 82% of plans covered Ozempic while only 1% covered Wegovy in 2024, the same drug denied or covered depending on the diagnosis on the prescription.
Employer plans are warming up slowly. In 2025, roughly 19% of firms with 200 or more workers covered GLP-1 medications for weight loss, and larger employers were more likely to. Even when a plan covers Wegovy, it rarely does so without conditions. Where plans use utilization management, about 96% require prior authorization before they will pay.
Read your denial letter before you do anything
Your next step depends entirely on the exact reason printed on the denial. The letter should name one of a few things: a prior authorization was required or never submitted, the plan judged the medication not medically necessary, step therapy requires you to try something else first, a quantity or dose limit applied, or your plan excludes weight-loss medication as a benefit. If the letter is vague, call the number on it and ask for the specific reason and the clinical criteria in writing.
That distinction matters because a missing prior authorization is very different from a hard exclusion. One is paperwork. The other is a coverage decision that an appeal rarely reverses.
Match the reason to your next step
Once you know the reason, our GLP-1 appeal decision flow maps each denial type to the step that actually helps, with no sign-up. In short: prior-authorization and medical-necessity denials call for your prescriber to submit documentation of your BMI, weight-related conditions, and prior attempts, then a formal appeal if the first submission is refused. Step-therapy and quantity denials usually need a short clinical justification or an exception request.
If your plan excludes weight-loss drugs
If the denial is a true benefit exclusion, be honest with yourself about the odds. Appealing an exclusion rarely works. The faster paths are a covered indication if one genuinely applies, a program like Medicaid where you are eligible, or paying cash. Brand self-pay through NovoCare and compounded semaglutide through licensed telehealth are frequently well below the pharmacy list price. We compare those routes in cash-pay GLP-1 options after a denial.
Appeal it with a free letter template
If your denial is workable, you do not need a lawyer or a paid service. Our appeal-letter template is free to copy or download, and it walks your prescriber through the medical-necessity points a reviewer looks for. Attach the original denial, a letter of medical necessity, your BMI and weight history, and records of prior weight-management attempts, then file before the deadline on your letter.
One note for Medicare: standard Part D does not cover weight-loss drugs, but the separate Medicare GLP-1 Bridge program offers Wegovy and the Zepbound KwikPen at about $50 per month from July 1, 2026 through December 31, 2027, with your prescriber submitting a prior authorization. That is a specific demonstration program, not general Part D coverage.
Sources: KFF ACA Marketplace GLP-1 coverage analysis (2024); KFF 2025 Employer Health Benefits Survey; IFEBP 2025 pulse survey; CMS Medicare GLP-1 Bridge fact sheet. Coverage rules and prices change often, so confirm current details with your plan and your denial letter.